FDA Clearance Tracker · P190032-S015
FoundationOne Liquid CDx
Last checked: Nov 20, 2026Latest source record: Nov 14, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Nov 14, 2024
Approved
Time to decision
379 days
Received Nov 1, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P190032-S015
- Device name
- FoundationOne Liquid CDx
- Applicant
- Foundation Medicine, Inc.
- Applicant location
- Boston, MA
- Received
- Nov 1, 2023
- Decided
- Nov 14, 2024
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P190032
Device type
- Device type
- Next generation sequencing oncology panel, somatic or germline variant detection system (PQP)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval order to expand the intended use of FoundationOne Liquid CDx (F1LCDx) (P190032/S015) to include a companion diagnostic indication to identify patients with non-small cell lung cancer harboring MET single nucleotide variants (SNVs) and insertions and deletions (indels) that lead to MET exon 14 skipping alterations who are eligible for treatment with Tepmetko® (tepotinib).
Source documents
Other decisions for Foundation Medicine, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- FoundationOne CDx (F1CDx)PMA supplement
P170019-S060 · Decided May 27, 2026 · 614 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- FoundationOne Liquid CDxPMA supplement
P190032-S029 · Decided May 27, 2026 · 490 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- FoundationOne CDxPMA supplement
P170019-S054 · Decided Jan 16, 2025 · 209 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.